Genentech has acquired SanegeneBio, a clinical-stage biotechnology company, for $1.7 billion. SanegeneBio, founded in 2021 by industry veterans, is a fully integrated company focused on the discovery and development of best-in-class genetic medicines, particularly using RNA interference (RNAi) technology. The company targets significant unmet medical needs in obesity, cardiometabolic, and autoimmune diseases.
Headquartered in Boston with R&D operations in both the U.S. and China, SanegeneBio has developed a proprietary technology platform called LEAD™ (Ligand and Enhancer Assisted Delivery). This platform is designed to enable tissue-specific silencing of disease-driving genes in the liver, adipose tissue, muscle, and immune cells through safe, infrequent subcutaneous dosing. SanegeneBio's approach is committed to advancing transformative RNAi therapies.
This acquisition represents a strategic move for Genentech, significantly expanding its capabilities and pipeline in the rapidly evolving field of genetic medicines and RNAi therapeutics. SanegeneBio's specialized LEAD™ platform and its clinical-stage programs in obesity, cardiometabolic, and autoimmune diseases are expected to complement Genentech's existing research and development efforts. The integration aims to accelerate the translation of innovative RNAi science into novel treatments.
The combination of SanegeneBio's deep RNAi expertise and proprietary technology with Genentech's extensive resources and global clinical development infrastructure is anticipated to create substantial synergies. This move is poised to enhance the pursuit of best-in-class genetic medicines, ultimately aiming to bring new, transformative therapeutic options to patients suffering from complex and underserved diseases.